Search

Displaying results 4451 - 4460 of 6835 in total
  1. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.

  2. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

  3. Drug

    Clobutinol

    go.drugbank.com/drugs/DB09004
    ApprovedWithdrawn

    In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

  4. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  5. Drug

    Shea butter

    go.drugbank.com/drugs/DB14311
    Approved

    Shea butter is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Ato Standard Premium Mildcream
  6. Drug

    GRAd-COV2

    go.drugbank.com/drugs/DB16428
    Investigational

    Preclinical and clinical studies show GRAd-COV2 to induce robust cellular and humoral immune responses[L30423]. … GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].

  7. Drug

    BB-301

    go.drugbank.com/drugs/DB17011
    Investigational

    [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062] … BB-301 is a modified AAV serotype 9 (AAV9) capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small

  8. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.

  9. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  10. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    Considered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent. … Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol.